Even when accounting for underlying lung disease, DLCO, 6MWD, hypoxemia, and BNP, PAH-specific therapy was still independently and significantly associated with reduced risk of mortality among patients with chronic lung disease and severe PH. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.